Key result
Pharmacogenomics and genotype-based individualized care for major anti-thrombotic drugs like warfarin and clopidogrel have become principal drivers for personalized therapy in clotting disorders.
Answers are grounded in this paper and cite their sources.
Pharmacogenomics and genetic testing for thrombophilic SNPs are increasingly incorporated into clinical decision-making for managing thrombotic disorders and anti-thrombotic therapy.
In terms of managing thrombotic disorders, genotype-based individualized patient care emerged as early as 1994 when the association of factor V Leiden (G1691A), and later, prothrombin (G20210A), with thrombotic phenotypes were discovered. Since then, genetic tests for specific thrombophilic SNPs have been routinely incorporated into daily practices in both thrombotic risk assessment and clinical decision-making with respect to prophylactic anti-thrombotic therapy. Recently, the area of pharmacogenomics in major anti-thrombotic drugs, such as warfarin and clopidogrel, has been the principal driver for personalized therapy based on one's own individual characteristics.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2009) conducted a review in Thrombotic disorders. Pharmacogenomics and genotype-based individualized care was evaluated. Pharmacogenomics and genotype-based individualized care for major anti-thrombotic drugs like warfarin and clopidogrel have become principal drivers for personalized therapy in clotting disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: